参考文献/References:
[1] Engelbertz C, Reinecke H, Breithardt, Günter, et al. Twoyear outcome and risk factors for mortality in patients with coronary artery disease and renal failure: The prospective, observational CAD-REF Registry[J]. International Journal of Cardiology, 2017: S0167527317304916. [2] 马丽媛,吴亚哲,王文,等.《中国心血管病报告 2017》要点 解读[J].中国心血管杂志,2018,23(1):3-6. [3] Kohei K, Kihei Y, Takanobu M, et al. Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease[J]. Archives of Medical Science, 2015(3):505-512. [4] Wu J, Chen C, Guo S, et al. Effect of Yiqihuoxue prescription on myocardial energy metabolism after myocardial infarction, via, cross talk of liver kinase B1-dependent Notch1 and adenosine 5′-monophosphateactivated protein kinase[J]. Journal of Traditional Chinese Medicine, 2017(3):104-112. [5] Antman E, Bassand J P, Klein W, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/ American College of Cardiology Committee[J]. Journal of the American College of Cardiology, 2000, 36(3):959-969. [6] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002. [7] Nasuv K, Terashima M, Habara M, et al. Impact of cholesterol metabolism on coronary plaque vulnerability of target vessels[J]. Cardiovascular Interventions, 2013, 6: 746-755. [8] Guo J, Wang S B, Yuan T Y, et al. Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflamation[J]. Atherosclerosis, 2013, 231(2):384-391. [9] Lee C S, Seo Y H, Yang D J, et al. Positive vascular remodeling in culprit coronary lesion is associated with plaque composision:an intravascular ultrasound-virtual histology study[J]. Korean Circulation Journal, 2012,42 (11):747-752. [10] Frangogiannis, N G. Regulation of the inflammatory response in cardiac repair[J]. Circulation Research, 2012, 110(1):159-173. [11] Frangogiannis N G. The immune system and cardiac repair[J]. Pharmacological Research, 2008, 58(2):88-111. [12] 周丽,黄立武.黄芪对冠心病心绞痛患者左室舒张功能及超氧化物歧化酶的影响[J].中国中西医结合杂志,1997 (12):723. [13] 冯津萍,卢奕,赵炳让,等.黄芪抑制家兔心肌缺血-再灌注 时细胞凋亡的实验研究[J].中国中西医结合急救杂志, 2001(1):14-16. [14] 张茂云,杨陆,牟宗毅.宣痹养心调肝法治疗冠心病稳定性 心绞痛失眠症[J].长春中医药大学学报,2016,32(2):119-120. [15] Christensen M K, Huang H, Torp-Pedersen C, et al. Incidence and impact on prognosis of peri-procedural myocardial infarction in 2760 elective patients with stable angina pectoris in a historical prospective follow-up study[J]. BMC Cardiovascular Disorders, 2016, 16(1):140. [16] 都基莎,何小丽,顾宁,等.益气活血方宁心痛颗粒治疗冠心 病心绞痛的研究思路初探[J].时珍国医国药,2013,24(1): 180-181. [17] 罗水泉.益气活血通痹汤治疗冠心病心绞痛临床观察[J].中国中医急症,2014,23(7):1368-1369. [18] 黄路梅,石立鹏,赵凤林,等.红花黄色素注射液联合左卡尼 汀治疗老年冠心病稳定型心绞痛 56 例[J].中国中医急症, 2017,26(3):473-475. [19] 侯王君,庄贺,薛一涛,等.应用中医传承辅助平台分析冠心 病不稳定型心绞痛方剂的组方用药规律[J].中国药房, 2017(32):20-24. [20] Mygind N D, Michelsen M M, Pena A, et al. Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: The iPOWER study[J]. Journal of the American Heart Association, 2016, 5(3):e003064. [21] Acar G, Kalkan M E, Avci A, et al. The Relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with stable angina pectoris and chronic total occlusion[J]. Clinical and Applied Thrombosis/Hemostasis, 2015, 21(5):462-468.